Updates
Cadila's Topical manufacturing facility successfully completes USFDA inspection.07-04-2017
Compliance Certificate Under Regulation 7(3) Of LODR - 2015 For The Half Year Ended March 31, 2017
We hereby certify that all activities in relation to both physical and electronic share transfer facilities are maintained by our Registrar and Share Transfer Agent i.e. Link Intime India Private Limited [Link Intime] having its branch at 5th Floor, 506 TO 508, Amarnath Business Centre 1 ( ABC-1), Beside Gala Business Centre, Nr. St. Xavier's College Corner, Off C G Road, Navrangpura, Ahmedabad - 380009. Further, we confirm that Link Intime is...06-04-2017
Cadila gets shareholders' nod for scheme of arrangement with Zydus Healthcare
Almost 100% shareholders have approved the scheme of arrangement between Cadila Healthcare and Zydus Healthcare01-04-2017
Disclosure of Voting results of Court Convened Meeting (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Cadila Healthcare Ltd has informed BSE regarding the details of Voting results of Court Convened Meeting, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here01-04-2017
Voting Results Of The Meeting Of Equity Shareholders Of The Company Held On March 30, 2017 Pursuant To The Final Order Passed By The National Company Law Tribunal [NCLT
Please find enclosed the voting results of the NCLT convened meeting of the Equity Shareholders of the Company held on March 30, 2017 at J B Auditorium, Ahmedabad Management Association, ATIRA Campus, Dr. Vikram Sarabhai Marg, Ahmedabad - 38001501-04-2017
Updates
We hereby inform that, Cadila Healthcare Limited has acquired all shares held by its subsidiary Companies in (1) Zydus Pharmaceuticals USA Inc., USA, (2) Zydus Healthcare USA LLC, (3) Zydus Noveltech USA, Inc. and (4) Bremer Pharma GmbH, Germany and therefore these four entities have become direct overseas subsidiary Companies. Please bring the aforesaid information to the notice of the members of the Exchange and the investors at large.30-03-2017
Updates
Please find attached herewith an updated Investors' Presentation for your kind ready reference.22-03-2017
Updates
We hereby inform that the Company has designated Dr. Sharvil P. Patel, the Deputy Managing Director as a Joint Managing Director. However, there is no change in other terms of his appointment.15-03-2017
USFDA nod for Zydus' muscle relaxant
Cadila Healthcare Ltd (Zydus Cadila) aid it has received final approval from the USFDA to market Tizanidine hydrochloride capsules, USP in strengths of 2mg, 4mg and 6mg. The drug, which is a muscle...09-03-2017
Zydus receives USFDA nod for muscle relaxant drug
Cadila Healthcare Ltd (Zydus Cadila), on Wednesday, said it has received final approval from the USFDA to market Tizanidine hydrochloride capsules, USP in strengths of 2mg, 4mg and 6mg. The drug,...08-03-2017